RAD17

Across TCGA pan-cancer cohorts, RAD17 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RAD17’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where RAD17 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RAD17 is over-expressed in tumor, although a few such as PDAC and COAD show the opposite, repressed pattern.

PDAC, CCRCC, and COAD are the cancer types where RAD17 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RAD17 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	II,III,IV	−0.255	.001	7	view →
CCRCC	All	II,III,IV	+0.105	.004	6	view →
COAD	Female	All	−0.677	.017	4	view →
LSCC	Male	All	+0.115	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RAD17–PDAC

Open the PDAC breakdown →